Clinical Application and Safety of Penpulimab Based on Real-World Study
Objective To investigate the clinical application and safety of penpulimab in the real world.Methods Thirteen patients treated with penpulimab from April to December 2022 in a cancer hospital were selected,and the patients' basic information,clinical diagnosis,medication information,and other clinical application and safety were retrospectively analyzed.Results Among the 13 patients,the gender ratio of male to female was 1∶1.6,the age was(61.1±14.5)years old,and 53.85%of the patients had chronic diseases.Off-label use of pembrolizumab occurred in clinical use,such as unapproved indications(100.00%)and combinations with other antineoplastic agents(76.92%).The incidence of adverse drug reactions(ADRs)was 23.08%,with two cases of grade Ⅲ ADRs,including diarrhea and liver function damage.Conclusion The ADRs of penpulimab are similar to the ADRs mentioned in the drug package insert,and the sample size should be further expanded to grasp the indications for use and ensure safe and rational medication.
国家科技期刊平台
NSTL
万方数据
